2-环丁基-2-羟基-2-苯基乙酸 | 1460-47-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-环丁基-2-羟基-2-苯基乙酸
• 英文名称: Cyclobutyl-phenyl-glykolsaeure
• 英文别名: 2-cyclobutyl-2-hydroxy-2-phenylacetic acid
• CAS: 1460-47-5
• 化学式: C₁₂H₁₄O₃
• mdl: MFCD00037149
• 分子量: 206.241
• InChiKey: ZHGXYXVTCLJDSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2918199090

反应信息

• 作为反应物：
  描述：

  2-环丁基-2-羟基-2-苯基乙酸 在 盐酸 、 甲醇 、 potassium carbonate 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 potassium iodide 作用下， 以 氯仿 、 乙腈 为溶剂， 反应 30.0h， 生成
  参考文献：
  名称：

  J-104129, a novel muscarinic M3 receptor antagonist with high selectivity for M3 over M2 receptors

  摘要：

  A new class of 4-acetamidopiperidine derivatives has been synthesized and investigated for human muscarinic receptor subtype selectivity. Introduction of a hydrocarbon chain of appropriate length into the piperidine nitrogen of the racemic N-(piperidin-4-yl)-2-cyclobutyl-2-hydroxy-2-phenylacetamide platform conferred up to 70-fold selectivity for human muscarinic M-3 receptors over M-2 receptors. Subsequent synthetic derivatizations resulted in highly potent M-3 receptor antagonists with selectivity greater than two orders of magnitude for M-3 over M-2 receptors, from which the analogue 4r was selected. Preparation of both enantiomers of 4r led to the identification of (2R)-N-[1-(4-methyl-3-pentenyl)piperidin-4-yl]-2-cyclopentyl-2-hydroxy-2-phenylacetamide (J-104129, (R)-4r), which exhibited 120-fold selectivity for Mg receptors (K-i = 4.2 nM) over M-2 receptors (K-i = 490 nM). In isolated rat trachea, (R)-4r potently and specifically antagonized acetylcholine (ACh)-induced responses with a K-B value of 3.3 nM. The highly subtype-selective profile was also seen in isolated rat tissue assays (50-fold) and in anesthetized rats (> 250-fold). Oral administration of J-104129 ((R)-4r) antagonized ACh-induced bronchoconstriction with an ED50 value of 0.58 mg/kg in rats. Thus, J-104129 ((R)-4r) may effectively facilitate bronchodilation in the treatment of obstructive airway disease. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00177-7
• 作为产物：
  描述：

  1-Hydroxy-1-cyclobutyl-1-phenyl-propin-(2) 、 potassium permanganate 、 Disodium;sulfite 、 水 在 乙醚 、 Sodium sulfate-III 、 ethyl acetate n-hexane 作用下， 反应 2.0h， 以to obtain the title compound (2.36 g, 36.8%)) as colorless prism的产率得到2-环丁基-2-羟基-2-苯基乙酸
  参考文献：
  名称：

  Arylacetic amide derivative or salt thereof, and pharmaceutical

  摘要：

  本发明涉及一种芳基乙酰胺衍生物，其化学式如下（1）所示：##STR1## 其中，R.sup.1表示芳基或类似物，R.sup.2和R.sup.3各自独立地表示烷基、环烷基或类似物，R.sup.4表示芳基烷基、烷基或类似物；或其盐。根据本发明的化合物具有优异的抗胆碱作用和钙拮抗作用，并且同时对膀胱具有高度选择性，因此可用作预防或治疗尿路障碍的药物。

  公开号：

  US06060485A1

文献信息

• [EN] 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS<br/>[FR] DERIVES D'AZABICYCLO [3.1.0] HEXANE 3,6-DISUBSTITUES UTILISES COMME ANTAGONISTES DU RECEPTEUR MUSCARINIQUE
  申请人：RANBAXY LAB LTD

  公开号：WO2004052857A1

  公开（公告）日：2004-06-24

  The invention relates to derivatives of 3,6-disubstituted azabicyclo [3.1.0] hexanes of structure (I). The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.

  这项发明涉及结构为(I)的3,6-二取代的氮杂双环[3.1.0]己烷衍生物。本发明的化合物可以作为肌碱受体拮抗剂，可用于治疗通过肌碱受体介导的呼吸系统、泌尿系统和消化系统的各种疾病。该发明还涉及含有本发明化合物的药物组合物以及治疗通过肌碱受体介导的疾病的方法。
• Analogs of oxybutynin. Synthesis and antimuscarinic and bladder activity of some substituted 7-amino-1-hydroxy-5-heptyn-2-ones and related compounds
  作者：J. Paul Carter、Lalita Noronha-Blob、Vicki H. Audia、Andrea C. Dupont、Daniel W. McPherson、Kenneth J. Natalie、W. Janusz Rzeszotarski、Ciro J. Spagnuolo、Philip P. Waid、Carl Kaiser

  DOI：10.1021/jm00114a016

  日期：1991.10

  its combined anticholinergic, antispasmodic, and local anesthetic activities. In a study directed toward development of agents possessing the beneficial properties of oxybutynin, but having a longer duration of action, a series of metabolically more stable keto analogues of the parent ester, i.e. substituted 7-amino-1-hydroxy-5-heptyn-2-ones along with some analogues and derivatives, was prepared and

  盐酸奥昔布宁[4-（二乙基氨基）-2-丁炔基α-环己基-α-羟基苯乙酸盐酸盐，二硝基泛]被广泛用于缓解神经源性膀胱的症状。这是由于其结合了抗胆碱能，抗痉挛和局部麻醉作用。在一项针对开发具有奥昔布宁有益特性但作用时间更长的药物的研究中，母体酯的一系列代谢更稳定的酮类似物，即取代的7-氨基-1-羟基-5-庚炔-制备了2-酮以及一些类似物和衍生物，并评估了豚鼠制剂中的体外和体内抗毒蕈碱作用。该系列的几个成员是有效的毒蕈碱类药物，在豚鼠膀胱造影图模型中，其活性持续时间比奥昔布宁更长。
• 1,4-di-substituted piperidine derivatives
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US05750540A1

  公开（公告）日：1998-05-12

  This invention provides novel 1,4-di-substituted piperidine derivatives of the general formula \x9bI! ##STR1## and the pharmaceutically acceptable salts thereof, wherein: Ar represents a phenyl group or a five- or six-membered heteroaromatic group having one or two hetero atoms selected from the group consisting of an oxygen atom, a sulfur atom and a nitrogen atom in which one or two optional hydrogen atoms on the ring may be replaced by substituent groups selected from the group consisting of a halogen atom and a lower alkyl group; R.sup.1 represents a cycloalkyl group of 3 to 6 carbon atoms or a cycloalkenyl group of 3 to 6 carbon atoms; R.sup.2 represents a saturated or unsaturated aliphatic hydrocarbon radical of 5 to 15 carbon atoms; and X represents O or NH. These compounds have selective antagonistic activity against the muscarinic M.sub.3 receptors and can hence be used safely with a minimum of side effects.

  该发明提供了一种新型的1,4-二取代哌啶衍生物，其通式为##STR1##及其药学上可接受的盐，其中：Ar代表苯基或含有一个或两个异原子（选自氧原子、硫原子和氮原子）的五元或六元杂环芳基，环上的一个或两个可选氢原子可被卤素原子和较低的烷基基团替代；R1代表3到6个碳原子的环烷基基团或3到6个碳原子的环烯烃基团；R2代表5到15个碳原子的饱和或不饱和脂肪烃基团；X代表O或NH。这些化合物对M.sub.3胆碱能受体具有选择性拮抗活性，因此可以安全地使用，并具有最少的副作用。
• [EN] 3,6-DISUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE 3,6-DISUBSTITUES AZABICYCLO HEXANE UTILISES EN TANT QU'ANTAGONISTES DU RECEPTEUR DE MUSCARINIQUE
  申请人：RANBAXY LAB LTD

  公开号：WO2004067510A1

  公开（公告）日：2004-08-12

  This invention generally relates to derivatives of 3,6 disubstituted azabicyclo hexanes.The compounds of this invention can function as muscarinic receptor antagonists and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors.The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.

  这项发明通常涉及3,6-二取代氮杂环己烷衍生物。本发明的化合物可以作为毒蕈碱受体拮抗剂发挥作用，并可用于治疗通过毒蕈碱受体介导的呼吸道、泌尿道和消化系统的各种疾病。该发明还涉及含有本发明化合物的药物组合物以及治疗通过毒蕈碱受体介导的疾病的方法。
• 3,6-Disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists
  申请人：Mehta Anita

  公开号：US20060217432A1

  公开（公告）日：2006-09-28

  The invention relates to derivatives of 3,6-disubstituted azabicyclo[3.1.0]hexanes of structure (I). The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.

  本发明涉及结构为（I）的3,6-二取代的氮杂双环[3.1.0]己烷衍生物。本发明的化合物可以作为毒蕈碱受体拮抗剂，可用于治疗通过毒蕈碱受体介导的呼吸系统、泌尿系统和消化系统的各种疾病。本发明还涉及含有本发明化合物的制药组合物以及治疗通过毒蕈碱受体介导的疾病的方法。